NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.345
-0.255 (-7.08%)
Aug 14, 2026, 4:00 PM EDT - Market closed
NewcelX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
18.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Werewolf Therapeutics | 21.00M |
| Marker Therapeutics | 3.55M |
| Cyclerion Therapeutics | 1.90M |
| Lipocine | 1.57M |
| Pluri | 1.08M |
NCEL News
- 14 days ago - NewcelX announces pricing of $1.4M equity financing - TheFly
- 14 days ago - NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - GlobeNewsWire
- 4 weeks ago - NewcelX announces Brazil patent for cell selection, enrichment technology - TheFly
- 4 weeks ago - NewcelX initiated with a Buy at Laidlaw - TheFly
- 5 weeks ago - NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - GlobeNewsWire
- 6 weeks ago - NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101 - TheFly
- 6 weeks ago - NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - GlobeNewsWire
- 2 months ago - NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - GlobeNewsWire